Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.02
+1.25 (+1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
44
45
Next >
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
Via
Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
December 08, 2022
Via
Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
December 07, 2022
Via
Benzinga
US Supports Delay On COVID Patent Waiver Extension Decision
December 06, 2022
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health...
Via
Benzinga
Is Amgen Stock a Buy for Income Investors?
December 02, 2022
Amgen's dividend yield is materially higher than the S&P 500 index's yield.
Via
The Motley Fool
Why Shares of Compugen Rose 16.5% on Wednesday
November 30, 2022
Market factors and a company announcement helped the stock climb.
Via
The Motley Fool
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
November 10, 2022
AZN earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Why AstraZeneca Stock Shot Higher Today
November 10, 2022
The company trounced analyst profitability estimates for its latest quarter and raised its guidance.
Via
The Motley Fool
2 Stocks That Could Surprise Investors in 2023
December 01, 2022
Investing in safe healthcare stocks may be an underrated strategy to deploy.
Via
The Motley Fool
Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
November 28, 2022
CNBC
Via
Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
November 28, 2022
Via
Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
November 23, 2022
There are reportedly numerous companies in the mix and they're all awaiting data next month.
Via
Investor's Business Daily
2 Breakout Growth Stocks to Buy for the Long Haul
November 19, 2022
These two Russell 1000 members know how to grow revenue.
Via
The Motley Fool
2 Stocks to Buy Whether or Not a Recession Is Coming
November 18, 2022
Both have outperformed the stock market this year.
Via
The Motley Fool
Why Shares of Compugen Jumped 17.86% on Thursday
November 17, 2022
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.
Via
The Motley Fool
How Long Can This Top Stock Continue Defying the Bear Market?
November 17, 2022
It could only be the beginning for this pharma giant.
Via
The Motley Fool
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Via
Benzinga
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
November 15, 2022
Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler...
Via
Benzinga
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
November 14, 2022
Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close...
Via
Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
Via
Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
November 11, 2022
Via
Benzinga
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
November 11, 2022
Via
Benzinga
AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth
November 10, 2022
Excluding exchange rates, AstraZeneca's sales surged 19% and came in above forecasts.
Via
Investor's Business Daily
Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11
November 10, 2022
Bloomberg
Via
Benzinga
Apple Hires Facebook Veteran as Information Chief; More Departures Likely
November 10, 2022
Via
Benzinga
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks
November 10, 2022
These stocks both pay more than 2% per year in dividends.
Via
The Motley Fool
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
November 10, 2022
Via
Benzinga
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target
November 09, 2022
Via
Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
November 09, 2022
Via
Benzinga
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
44
45
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.